...
首页> 外文期刊>International Journal of Hypertension >Cardiovascular Risk Factors and Chronic Kidney Disease—FGF23: A Key Molecule in the Cardiovascular Disease
【24h】

Cardiovascular Risk Factors and Chronic Kidney Disease—FGF23: A Key Molecule in the Cardiovascular Disease

机译:心血管危险因素和慢性肾脏病—FGF23:心血管疾病的关键分子

获取原文
           

摘要

Patients with chronic kidney disease (CKD) are at increased risk of mortality, mainly from cardiovascular disease. Moreover, abnormal mineral and bone metabolism, the so-called CKD-mineral and bone disorder (MBD), occurs from early stages of CKD. This CKD-MBD presents a strong cardiovascular risk for CKD patients. Discovery of fibroblast growth factor 23 (FGF23) has altered our understanding of CKD-MBD and has revealed more complex cross-talk and endocrine feedback loops between the kidney, parathyroid gland, intestines, and bone. During the past decade, reports of clinical studies have described the association between FGF23 and cardiovascular risks, left ventricular hypertrophy, and vascular calcification. Recent translational reports have described the existence of FGF23-Klotho axis in the vasculature and the causative effect of FGF23 on cardiovascular disease. These findings suggest FGF23 as a promising target for novel therapeutic approaches to improve clinical outcomes of CKD patients.
机译:慢性肾脏病(CKD)患者的死亡风险增加,主要是心血管疾病。此外,异常的矿物质和骨骼代谢,即所谓的CKD-矿物质和骨骼疾病(MBD),是从CKD的早期开始发生的。 CKD-MBD对CKD患者具有很强的心血管风险。成纤维细胞生长因子23(FGF23)的发现改变了我们对CKD-MBD的理解,并揭示了肾脏,甲状旁腺,肠和骨骼之间更复杂的串扰和内分泌反馈回路。在过去的十年中,临床研究的报告描述了FGF23与心血管风险,左心室肥大和血管钙化之间的关系。最近的翻译报道描述了血管系统中存在FGF23-Klotho轴,以及FGF23对心血管疾病的致病作用。这些发现表明FGF23是改善CKD患者临床结局的新型治疗方法的有希望的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号